AIM To characterize antiviral therapy eligibility among hepatitis B virus(HBV)-infected adults at a university hospital in *** Hepatitis B surface antigen-positive adults(n = 160) who were h IV-negative and referred t...
详细信息
AIM To characterize antiviral therapy eligibility among hepatitis B virus(HBV)-infected adults at a university hospital in *** Hepatitis B surface antigen-positive adults(n = 160) who were h IV-negative and referred to the hospital after a routine or clinically-driven HBV test were enrolled. Alanine Aminotransferase(ALT),Aspartate Aminotransferase(AST),platelet count,hepatitis B e-antigen,and HBV DNA were measured. Liver fibrosis/cirrhosis was assessed by physical examination,AST-to-platelet ratio index,and transient elastography. In antiviral therapy-na?ve individuals,we described hBV stages and antiviral therapy eligibility per World health Organization(WhO) and by hBV test(routine vs clinical). Elevated ALT was > 19 in women and > 30 U/L in men. Among treatmentexperienced individuals,we described medication side effects,adherence,and viral *** The median age was 33 years,71.9% were men,and 30.9% were diagnosed with HBV through a clinicallydriven test with the remainder identified via routine testing(at the blood bank,community events,etc.). Among 120 treatment-na?ve individuals,2.5% were categorized as immune tolerant,11.7% were immune active,35.6% were inactive carriers,and 46.7% had an indeterminate phenotype. Per WhO guidelines,13(10.8%) were eligible for immediate antiviral therapy. The odds of eligibility were eight times higher for those diagnosed at clinical vs routine settings(adjusted odds ratio,8.33; 95%CI: 2.26-29.41). Among 40 treatmentexperienced hBV patients,virtually all took tenofovir,and a history of mild side effects was reported in 20%. Though reported adherence was good,12 of 29(41.4%) had HBV DNA > 20 IU/m L. CONCLUSION Approximately one in ten HBV-monoinfected Zambians were eligible for antivirals. Many had indeterminate phenotype and needed clinical follow-up.
The present study reports the in vivo anti-Mycobacterial Activity of a Phytomedicine “MATHESIA” on Mycobacterium ulcerans. It also explores the influence of ethanolamine (alkali agent) on the in vivo activity of som...
详细信息
The present study reports the in vivo anti-Mycobacterial Activity of a Phytomedicine “MATHESIA” on Mycobacterium ulcerans. It also explores the influence of ethanolamine (alkali agent) on the in vivo activity of some antibiotics (Isoniazid, Rifampicin, Ethambutol) used in the treatment of Buruli ulcers in DR Congo. Experiments were conducted on adult white Wistar rats of both sexes with the weights comprising between 110 - 165 g. The result obtained have shown that the phytomedicine MATHESIA (pH 10) has a good in vivo activity on M. ulcerans and the duration for wounds healing and total cicatrization was 6 days;whereas this duration was 10, 12, 14, and 16 days respectively for Rifampicin (I
暂无评论